Alerta

Small red bean polypeptide for preventing and treating ulcerative colitis and application thereof

Resumen de: CN121991171A

The invention belongs to the technical field of bioactive peptides, and provides a small red bean polypeptide for preventing and treating ulcerative colitis and application of the small red bean polypeptide, and the amino acid sequence of the small red bean polypeptide is IFNNDPNNHP. The small red bean polypeptide can significantly reduce the DAI score of a mouse with DSS colitis, relieve the shortening of the colon length of the mouse with DSS colitis and improve the erosion and ulcer degree of the colonic mucosa, and has good prevention and treatment effects on ulcerative colitis; meanwhile, the preparation method is simple and easy for industrial production; certain drug research and development and clinical application values are realized.

NON-INVASIVE METHODS AND DEVICES FOR MONITORING MICROBIOME HEALTH

Resumen de: WO2026097001A2

The present disclosure is related to ex vivo methods and devices for identifying a presence of or predicting a risk for a condition in a subject, wherein the risk or condition is correlated with an oxidation-redox potential (ORP) of a biological sample obtained from the subject, such as a fecal sample. The methods and devices of the present disclosure can be used to diagnose and monitor gut microbiome health and assess the risk and/or presence of conditions such as obesity, metabolic dysfunction associated steatotic liver disease (MASLD), type 2 diabetes, hyperlipidemia, hypertension, cardiovascular disease, a gut specific condition, irritable bowel syndrome, an inflammatory bowel disease, ulcerative colitis, Crohn's disease, a Clostridium difficile infection, or any combination thereof based on an ORP of the subject's sample.

ASSAY FOR MONITORING CROHN'S DISEASE AND MITOCHONDRIAL DYSFUNCTION

Resumen de: WO2025003436A1

The present application provides an ultrasensitive colorimetric assay as well as an early biomarker for patient monitoring and medical treatment of patients suffering from a possible mitochondrial dysfunction, inflammatory bowel disease, particularly Crohn's disease. The ultrasensitive colorimetric assay measures the level of L-citrulline in a plasma or serum sample; and when the level of L-citrulline in plasma or serum decreases or falls even below 30 µmol L-citrulline, this indicates a mitochondrial cell disorder caused by a relapse or an increase in intestinal inflammation due to a flare of Crohn's disease. A method of detecting and treating the mitochondrial dysfunction is also provided.

Application of ANKRD13A as target spot in preparation of anti-enteritis drugs

Resumen de: CN121971613A

The invention provides application of ANKRD13A as a target spot in preparation of an anti-enteritis drug, relates to the technical field of biomedicine, and is technically characterized in that application of ANKRD13A as a target spot in preparation of an anti-enteritis drug is provided. According to the application, the mRNA expression level of ANKRD13A in intestinal mucosa of adult and pediatric ulcerative colitis (UC) patients is proved to be obviously lower than that of a healthy control group by analyzing a GEO public data set; an Ankrd13a gene knockout mouse model is constructed, and it is found that gene deletion in a steady state does not affect colon development and functions; after acute colitis is induced by DSS, the death rate of knockout mice is increased, the colitis susceptibility is increased, the colon is shortened, intestinal epithelium injury is aggravated, and immune cell infiltration is increased. According to the application, the key regulation effect of the ANKRD13A in ulcerative colitis is defined, an experimental basis is provided for developing the ANKRD13A as an anti-enteritis drug target and a diagnostic marker, and the related drug can be used for preventing and treating enteritis.

Radiopharmaceutical and application thereof

Resumen de: CN121971661A

The invention provides a radiopharmaceutical and application thereof, and relates to the technical field of nuclear medicine, the radiopharmaceutical provided by the invention can be used as an integrin alpha4beta7 imaging agent, and imaging diagnosis can be carried out on focuses of diseases (such as inflammatory bowel diseases or tumor diseases) related to positive expression of integrin alpha4beta7 by utilizing a PET imaging technology of nuclear medicine. A chelating part in the integrin alpha4beta7 radiopharmaceutical can be replaced by NOTA chelating agents, NODAGA chelating agents, DOTAGA chelating agents, THP chelating agents and TRAP chelating agents, and the integrin alpha4beta7 radiopharmaceutical can be used for labeling < 68 > Ga metal nuclides, < 61 > Cu metal nuclides, < 64 > Cu metal nuclides and < 177 > Lu metal nuclides, so that PET imaging and nuclide treatment of various nuclides are further realized.

Protein marker for differential diagnosis of intestinal extracorporeal natural killer/T cell lymphoma and application of protein marker

Resumen de: CN121955382A

The invention discloses a protein marker for differential diagnosis of intestinal extracorporeal natural killer/T cell lymphoma and application of the protein marker. The protein marker is composed of COL6A3 and MFAP2 protein. Or the protein is composed of ADAMTS4, COL6A3 and MFAP2 protein. The invention also provides application of a reagent for detecting the protein in preparation of a kit for diagnosing intestinal natural killer cell/T cell lymphoma or evaluating the occurrence risk of the intestinal natural killer cell/T cell lymphoma. According to the invention, the technical bottleneck of difficulty in pathological diagnosis caused by superficial endoscopic biopsy sample of the intestinal ENKTL is effectively solved, and ENKTL can be accurately identified from ulcerative colitis, diffuse large B-cell lymphoma and colon cancer. The method is simple and convenient to operate, the selected antibody is strong in signal and clear in background in IHC detection, a quantitative result with good repeatability and high specificity can be obtained by combining an H-score scoring system, and objectivity and accuracy of pathological diagnosis are remarkably improved.

Intestinal Rosebaria sp. Capable of promoting intestinal bacteria to produce valeric acid and application of composition of intestinal Rosebaria sp. In relieving ulcerative colitis

Resumen de: CN121950604A

The invention discloses an application of intestinal Rosebaria capable of promoting intestinal bacteria to produce valeric acid and a composition of the intestinal Rosebaria in relieving ulcerative colitis, and belongs to the technical field of microorganisms. According to the intestinal Rosiberia NSP017 disclosed by the invention, the konjac glucomannan can be quickly utilized, and the composition of the intestinal Rosiberia and the konjac glucomannan can be used for improving the disease activity index and spleen enlargement of a mouse with ulcerative colitis, maintaining the integrity of an intestinal barrier, reducing the oxidative stress level, and improving the ulcerative colitis activity index and the spleen enlargement of the mouse with ulcerative colitis, so that the intestinal Rosiberia NSP017 can be used for treating ulcerative colitis. The level of a clinical diagnosis marker for colitis is remarkably reduced, the effect is superior to that of a clinical medicine mesalazine, and it is found that the intestinal Rosebawnella NSP017 can promote intestinal bacteria of mice with colitis to recover the capacity of producing valeric acid. The intestinal Rosibula sp. NSP017 and the composition of the intestinal Rosibula sp. NSP017 have very wide application prospects in the aspect of preparing foods, pharmaceutical compositions, health-care products or feed additives for relieving ulcerative colitis.

SYSTEM AND METHOD FOR DETERMINING A STOOL CONDITION

Resumen de: US20260114804A1

0000 Disclosed herein, in some aspects, are systems and methods for determining and/or monitoring a stool condition for a subject. In some embodiments, the stool condition is based on one or more images of stool of a subject. In some embodiments, the stool condition correlates with a stool assessment comprising i) a characterization of the stool according to a plurality of characteristics, and/or ii) identifying one or more medical conditions, illnesses, and/or diseases associated with the stool. In some embodiments, the stool condition is determined using one or more Artificial Intelligence engines using a trained data set. In some embodiments, the stool condition is based on one or more stool assessments performed for one or more stools corresponding to one or more bowel movements over a period of time.

METHODS OF TREATING A PATIENT WITH AN INFLAMMATORY BOWEL DISEASE

Resumen de: AU2024362918A1

This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.

TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE

Resumen de: AU2024354463A1

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

TL1A结合分子及其应用

Resumen de: CN121930341A

本发明提供了TL1A结合分子及其应用。具体地，本发明提供了抗TL1A单域抗体或其抗原结合片段，其能够与人和食蟹猴TL1A结合，阻断TL1A/DR3通路，但不影响TL1A与TL1A/DR3通路的天然阻断剂DcR3的结合。本发明的抗TL1A单域抗体或其抗原结合片段与TL1A的结合具有pH依赖性，更有利于在体内长期循环，延长半衰期。因此，本发明的抗TL1A单域抗体或其抗原结合片段可作为新型治疗剂，应用于免疫炎症相关疾病的治疗。

SH3YL1 Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof

Resumen de: US20260109755A1

0000 The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.

Application of reagent for detecting tsRNA molecular marker in intestinal mucosa tissue in preparation of Crohn disease diagnostic kit

Resumen de: CN121896348A

The invention belongs to the technical field of biological medicine, and particularly discloses application of a reagent for detecting a tsRNA molecular marker in intestinal mucosa tissue to preparation of a Crohn disease diagnostic kit, the reagent is characterized in that the tsRNA molecular marker is tRF-28-PW5SVP9N1503, the sequence of the tsRNA molecular marker is GCCGTGATAGTGGTTAGTACTCT, the reagent for detecting the tsRNA molecular marker in the intestinal mucosa tissue comprises tRF-28-PW5SVP9N1503 fluorescent quantitative PCR upstream and downstream primers, and the primer sequence of the tsRNA molecular marker in the intestinal mucosa tissue is shown in the description. The upstream primer is AATG CCGTGATCGTATAGTGGTT, and the downstream primer is TATCCTTGTTGACGACTGGTTGAC, and the downstream primer is The method has the advantages that absolute quantitative detection of target molecules can be rapidly and accurately completed only with a small amount of samples, and the method is used for early screening and identification of Crohn's disease and is high in sensitivity and specificity.

Method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry

Resumen de: CN121878075A

The invention belongs to the field of analytical chemistry, and provides a method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry, differentiated pretreatment schemes are designed aiming at different biological matrixes such as excrement, serum, colon tissue and NCM460 inflammatory cells through a liquid chromatography-tandem mass spectrometry technology, matrix interference is effectively eliminated, and the method for simultaneously determining 10 tryptophan metabolites through liquid chromatography-mass spectrometry is provided. A quantitative analysis method with high sensitivity and high selectivity is established; the method is successfully applied to an ulcerative colitis (UC) rat model and a lipopolysaccharide (LPS)-induced NCM460 inflammation model, and a technical means is provided for revealing a metabolic regulation mechanism of medicine intervention on UC; the method solves the technical problem that various metabolites in a tryptophan metabolic pathway are difficult to detect in the prior art, is suitable for metabolic mechanism research, drug intervention effect evaluation and large-scale detection of clinical samples of inflammatory bowel diseases such as UC, and provides a technical basis for systematic research of a tryptophan metabolic network.

METHODS AND SYSTEMS FOR DETECTION OF PRE-CANCER

Resumen de: WO2026080407A1

Provided herein are methods and systems for detection of precancer or cancer. The method may comprise using cell-free nucleic acids. The methods may comprise assaying nucleic acids. The method may comprise extracting cell-free nucleic acids. The methods may comprise generating libraries based at least on cell-free nucleic acids.

Crohn disease early diagnosis marker screening method fusing multiple omics data

Resumen de: CN121838867A

The invention discloses a Crohn disease early diagnosis marker screening method fused with multi-omics data. The method comprises the following steps: constructing a Crohn disease evolution time sequence specificity multi-omics sample set, and synchronously obtaining genome, transcriptome, proteome and metabolome data through longitudinal sampling; a deep multi-omics time sequence fusion network model is constructed and applied to screen a candidate marker set, the network realizes multi-dimensional data deep integration through a multi-omics feature coding layer and a cross-omics cross attention fusion layer, and an evolution law of markers is captured through a time sequence dynamic modeling layer; the technical problems that in an existing marker screening method, multi-omics data integration is shallow, disease dynamic time sequence information is neglected, and a verification system is incomplete are solved, and the Crohn disease early diagnosis marker with high sensitivity and specificity can be efficiently and accurately screened out from complex multi-omics data; and the accuracy and clinical transformation potential of early diagnosis are remarkably improved.

Multi-constraint adaptive multi-modal fusion inflammatory bowel disease risk prediction method

Resumen de: CN121839141A

The invention provides a multi-constraint adaptive multi-modal fusion inflammatory bowel disease risk prediction method, which is applied to the crossing field of medical data processing and machine learning and is suitable for early diagnosis and clinical risk stratification of inflammatory bowel diseases. According to the method, multi-modal omics data related to the inflammatory bowel disease is collected, and a three-level bioinformatics filtering strategy is adopted for preprocessing; each piece of preprocessed modal data is coded, and modal orthogonal constraint is applied to retain modal specificity; dual-stage dynamic fusion is realized through a hierarchical attention mechanism, and modal weights are adaptively distributed; supervised comparative learning and maximum mean value difference loss are introduced, and feature discrimination and distribution consistency are enhanced; and finally, outputting an inflammatory bowel disease risk prediction result based on the fusion features. According to the method, high-dimensional redundant features are effectively compressed, the overfitting risk is reduced, modal specificity and complementarity are considered, the model generalization ability and subtype discrimination precision are improved, and reliable technical support is provided for early diagnosis of the inflammatory bowel disease.

一种炎症性肠病诊断用细胞外囊泡蛋白质标志物及应用

Resumen de: CN121831162A

本发明涉及分子诊断技术领域，公开了一种炎症性肠病诊断用细胞外囊泡蛋白质标志物及应用，该标志物源于血浆细胞外囊泡膜蛋白，包括用于诊断克罗恩病的组分I、诊断溃疡性结肠炎的组分II及鉴别用的组分III。本发明采用聚合物沉淀结合超速离心法提取囊泡，利用抗体寡核苷酸偶联探针及邻近条形码分析技术进行高通量检测。结合机器学习算法对囊泡亚群进行聚类分析，应用该标志物制备的试剂盒，通过检测特定蛋白组合及细胞外囊泡亚群比例，实现了炎症性肠病的无创筛查、早期诊断及亚型精准鉴别，有效解决了现有单一标志物诊断盲区与个体异质性问题，具有高灵敏度、高特异性及非侵入性优势。

Method and system for detecting relation between full sibs and half sibs of poultry

Resumen de: CN121811960A

The invention discloses a poultry full-sib and half-sib relationship detection method and system, and relates to poultry breeding. The method comprises the following steps: obtaining samples of N poultry individuals in a poultry group to be detected, and extracting DNA (Deoxyribose Nucleic Acid); performing genetic typing on N poultry individuals by using a high-density SNP chip to obtain a genotype matrix M; performing quality control on the genotype matrix M, and filtering the SNP markers with the detection rate lower than a first preset threshold value or the minimum allele frequency MAF lower than a second preset threshold value to obtain a genotype matrix after quality control; according to the genotype matrix, calculating an IBS similarity coefficient and a genome genetic relationship coefficient GRC between any two individuals i and j; according to the poultry with known genetic relationship, IBS similarity coefficient distribution and genome genetic relationship coefficient GRC distribution of full-sib, half-sib and non-sib relationships are respectively counted, and 95% confidence interval of each category is calculated. The method improves the classification precision.

Differentiation Method for an Intestinal Epithelial Monolayer Model Derived from Duodenal Organoids of Crohns Disease Patients

Resumen de: KR20260045660A

본 발명은 크론병 환자 십이지장 오가노이드 유래 장 상피 단층 모델의 분화 방법에 관한 것으로, 발명의 장 상피 단층 모델은 3차원 십이지장 오가노이드로부터 해리된 단일 세포에 기초하여 분화를 유도한 것으로, 다양한 장 상피 세포 유형을 포함하고 내강(lumen)에 대한 접근성을 제공한다. 또한, 본 모델은 실제 환자 장 점막의 구조와 기능을 효과적으로 모사할 수 있어 염증성 장질환을 포함한 다양한 장 질환의 병태생리 연구뿐만 아니라, 후보 물질의 효능 및 안전성을 평가하는 데 유용하게 활용될 수 있다.

N-ACYL AMIDES AND ANALOGS

Resumen de: WO2026072849A2

The present disclosure provides pharmaceutical compositions, dosage forms comprising the pharmaceutical composition, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, and treating colorectal cancer in a subject in need thereof, comprising administering the pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof.

METHODS OF DETECTING MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS

Resumen de: WO2026064841A1

The present invention relates in part to methods of detecting Mycobacterium avium subsp. paratuberculosis in ruminant animals and markers for use in such methods.

Method of diagnosing a dysbiosis

Resumen de: AU2026201512A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS). eb e b

Preparation method of non-metal magnetic resonance imaging nano diagnosis and treatment agent with controllable morphology

Resumen de: CN121754690A

The invention belongs to the technical field of magnetic resonance imaging nano diagnosis and treatment agents, and particularly relates to a preparation method of a shape-controllable nonmetal magnetic resonance imaging nano diagnosis and treatment agent. According to the preparation method, 2-(perfluorooctyl) ethyl methacrylate (HDFDMA) and methacrylic acid-2, 2, 6, 6-tetramethyl-4-piperidinyl ester (m-TEMPO) are taken as monomers to prepare shape-controllable sugarcoated haw-shaped nano-particles (WNPT), electronegative tannic acid (TA) is loaded after oxidation, and the shape-controllable sugarcoated haw-shaped nano-particles are prepared through a polymerization-induced self-assembly method. The nanometer diagnosis and treatment agent TA (at) WNPT with a magnetic resonance imaging (MRI) function and a colitis treatment function is obtained. According to the method disclosed by the invention, polymerization and assembly are synchronously carried out under the condition of high concentration, and the morphology, size and surface chemical characteristics of the nanoparticles are accurately regulated and controlled. It is proved for the first time that in the nonmetal MRI probe, compared with spherical particles, the sugarcoated haw-shaped structure can remarkably improve the MRI performance.

DIETARY MACRO/MICRONUTRITIONAL COMPOSITIONS AND APPLICATIONS THEREOF

Nº publicación: US20260083739A1 26/03/2026

Solicitante:

DABDOUB ATIF [US]
DABDOUB Atif

Resumen de: US20260083739A1

Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.